Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Discover how groundbreaking research on unique immune cells and advanced AI tools offers renewed hope for improving cancer ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

The following is a summary of “Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, ...

Columbia Engineering and Irving Institute researchers unveil a significant finding in cancer immunotherapy, uncovering unique ...

Cell types detected in the bone marrow of a responder patient pre-treatment (left) and post-treatment (right). Contour lines mark cell groups with similar spatial neighborhoods, highlighting ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from ...

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

“Studies have shown that healthcare utilization at the end of life is high, and patients receive aggressive medical care that ...